AP338A - A carbamoylchroman compound as selective 5-hydroxytryptamine. - Google Patents
A carbamoylchroman compound as selective 5-hydroxytryptamine. Download PDFInfo
- Publication number
- AP338A AP338A APAP/P/1992/000434A AP9200434A AP338A AP 338 A AP338 A AP 338A AP 9200434 A AP9200434 A AP 9200434A AP 338 A AP338 A AP 338A
- Authority
- AP
- ARIPO
- Prior art keywords
- compound
- isopropyl
- propylamino
- carbamoylchroman
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Abstract
3-(N-I
Description
Field of the Invention
The present invention relates tc the new compound 3-(N5 i sop r spy 1 -iJ-n -propyl ami no )-5-( N- isopropyl) carbamoy 1 chroman in the racemic form as well as the iR)-enantiomer thereof m the form of free case or pharmaceutitally acceptable salts thereof, process for their preparation, pharmaceutical compositions containing said therapeutic10 ally active compound and to the use of said active compound in therapy.
An object of the invention is to provide a compound for therapeutic use, especially a compound having a highly selective affinity for a subgroup of 5-hydroxytryptamine receptors '-·ΗΤΙΑ5 -o the central nervous system (CNS; -f mammals including man.
It is also an object of the invention to provide a compound with a therapeutic effect after oral administration.
Prior art
Substituted-3-aminochromans intended for therapeutic use in the central nervous system are disclosed in some patent documents inter alia EP 0 222 996 and WO 91/09853.
Background of the Invention
0
Various central nervous system disorders such as depression, anxiety, etc. appear to involve the disturbance of the neurotransmitters noradrenaline (NA) and 5-hydroxytryptamine (5-HT), the latter also known as serotonin.
The drugs most frequently used in the treatment of depression are believed to act by improving the neurotransmission of either or both of these physiological agonists. It appears that the enhancement of 5-HT neurotransmission primarily affects the depressed mood
BADOBIQ'NAL §)
and anxiety, whereas the enhancement of noradrenaline nearctransm:ssion afreets the retardation symptoms occuring in depressed patients. The invention concerns compounds which have an effect on 5-HT neurotransmissicn.
Serctcnm, cr 5-HT, activity is thought to be involved m many different types of psychiatric disorders. For instance it is thought that an increase in 5-HT activity is associated with anxiety, while a decrease in 5-HT release has been associated with depression. Serotonin has in addition been implicated in such diverse conditions as eating disorders, cardiovascular regulation and sexual behavior .
The 5-HT Receptors
The various effects of serotonin may be related to the fact that serotonergic neurons stimulate the secretion cf severeal other hormones, e.g. cortisol, prolactin, β-endorphin, vasopressin and others. The secretion of each of these other hormones appears to be regulated on a specific basis by several different 5-HT (serotonin) receptor subtypes. With the aid of molecular biology techniques, to date these receptors have been classified as 5-HT^, 5-HT2, 5-HTj, and 5-HT^ with the 5-HT^ receptor further divided into the 5-HT^, 5-ΗΤ^β/ 5-HT^^ and
5-HT^d subtypes. Each receptor subtype is involved in a different serotonin function and has different properties .
5-HT-Receptor-Active Agents
The mechanism of action for the drugs generally used today in the therapy of mental depression is indirect,
i.e. they act by blocking the re-uptake of the neurotransmitters (NA and/or 5-HT) released from nerve terminals in the central nervous system. These drugs
BAD ORIGINAL fi
AP 0 0 0 3 3 8 increase the concentration of the neurotransmitters in the synaptic cleft and hence restore adequate neurotransmission .
A fundamentally different way of improving the neurotransmission in the central nervous system 5-HT neurons would be to use a direct 5-HT-receptor-active agent. In order to minimize side effects, or to effect a specific type of behavior or serotonin function, a high selectivity for a specific 5-HT receptor subtype would be preferred. Agonists can be used to activate specific receptors.
The object of the present invention is to provide compounds for therapeutic use, especially for treatment of
5-hydroxytryptamine mediated disorders in the central nervous system for instance depression, anxiety, obsessive-compulsive disorder (OCD,, anorexia, senile dementia, migraine, stroke, Alzheimer's disease, hypertension, thermoregulatory and sexual disturbances, pain and for treatment of disturbances in the cardiovascular system.
The invention
It has turned out that various 3-(N,N-dialkylamino)-5(N-alkyl)carbamoylchromans tested, show a great variability in the three different parameters bioavailability,
5-HTIA receptor stimulating effect and in selectivity. It has been difficult to identify compounds possessing all three advantageous properties. There is no guidance in the prior art how to obtain compounds with this combination of properties.
Surprisingly, it has been found that the racemic compound of the invention, 3-(N-isopropyl-N-n-propylamino)-5(N-isopropyl) carbamoylchroman shows excellent bioavailability, and possess a high affinity to a specific subBAD ORIGINAL ft group of 5-hydroxytryptamine receptors in CNS, the
las been found that high affinity for the
5-KT,.-receptor in CNS is strictly stereospecific as regards the ccmpcund, 3N-isopropyl-N-n-propylaminoj-5ίΝ-isopropyl)carbamoylchroman. The (R)-enantiomer of 3-(N-isopropyi-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman possesses a high affinity for 5-HTIA receptors in CNS while the (S)-enantiomer of 3- (N-isopropyl-N-npropylamino)-5-(N-isopropyl)carbamoylchroman lacks activity for 5-HTIA receptors. The (R)-enantiomer of 3 -(N-isopropyl-N-n-propylamino)-5-(N-isopropyl) carbamoyl chroman shews a good bioavailability, too. Thus the racemate as weii as the (R)-enantiomer of the compound t: the invention can be used in the treatment of 5-hydroxytryptamine mediated states and disorders in mammals including man.
The compound of the present invention is 3-(N-isopropylN-n-propylamino) -5- (N-isopropyl)carbamoylchroman as racemate and (R)-enantiomer having the formula in the form of free base or pharmaceutically acceptable salts thereof.
Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compound of this invention. Illustrative acids are sulfuric, nitric, phosphoric, oxalic, hydrochloric, formic, hydrobromic, citric, acetic, lactic, tartaric,
BAD ORIGINAL Ά
AP O Ο Ο 3 3 8 dibenzoyltartaric, diacetyltartaric, pamoic, ethar.edisulfonic, sulfamic, succinic, propionic, glycollic, malic, gluconic, pyruvic, phenylacetic, 4-aminobenzoic, anthramlic, salicylic, 4-aminosalicylic, 4-hydroxyΐ benzoic, 3,4-dihydroxybenzoic, 3,5-dihydroxybenzoic,
3-hydrcxy-2-naphtoic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benzenesulfonic, p-toluenesulfonic, sulfamlic, naphthalenesulfonic, ascorbinic, cyclohexylsulfamic, fumaric, maleic and benzoic acids. These salts are readily prepared by methods known in the art.
Preparation
The ( FJ-enar.t icmer may be obtained according to known .: .methods such as from racemic diastereomeric salts by means of fractional crystallisation or covalent diastereomers by means of chromatography. The enantiomeric separation may be performed before alkylation of the amino group (Method A) or after
N-alkylation (Method B). The scheme below illustrates the Methods A and B in more detail:
Method A
Method B
Enantiomeric separation
NH.
OCHEnantiomeric separation (III)
BAD ORIGINAL &
The cor,pound V ray be transferred to compound VI by using known method steps such as N-alkylation, demethylation and finally conversion to the leaving group Y.
The preparation of the racemic compound of the invention may start from, the compound 5-methoxy-3-chromanone iprepared analogously to the description in EP 222 996) followed by known methods such as reductive amination, N-alkylation, demethylation and finally conversion to the leaving group Y to obtain the racemate of compound VI.
The racemic form as well as the (R)-enantiomer of the compound of the invention, may be prepared according to the following .methods:
t vii ) / iib
BAD ORIGINAL
AP Ο Ο Ο 3 3 β converting the compound of formula VI
wherein Y is a leaving group such as trifluoromethane 10 sulfonate (OSC^CF^), halide e.g. Cl, or Br or I by a catalytic cycle using a zerovalent transition metal (Mi such as Pd or Ni, which may be generated in situ and undergoes an oxidative addition to the aryl-Y-bond. Treatment with carbon monoxide followed by amination with isopropylamine give the the compound of formula I, whereafter if desired it is converted tc a salt.
ii, Alternatively, the compound of formula VI is converted to the compound of formula VII
wherein Z is Cl, Br, OH or ORp, where Rp is C^-Cg alkyl, by catalytic cycle using a zerovalent transition metal, with ability to undergo oxidative addition to aryl-Y30 bonds e.g. the aryl-SO^CF^ bonds. The aryl-CO-metal-Y complex is formed by treatment with carbon monoxide (CO).
Further reagents are an alcohol such as methanol, ethanol, a tertiary amine base such as a trialkylamine
e.g. triethylamine in an inert organic solvent preferentially a polar aprotic solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetone,
BAD ORIGINAL acetonitrile etc. The reaction is normally performed at a temperature between +40 to +120°C and at a pressure between 100 to 500 KPa (iia!. This is optionally followed by hydrolysis and treatment with a thionyl halide, e.g.
thionyichloride, to obtain the corresponding acid halide derivative.
The compound of formula VII is aminated (iib) with isopropylamine in a nonpolar aprotic solvent e.g. toluene, benzene at reflux temperature or between 0 to 100°C to give the compound of formula I.
Pharmaceutical preparations
According to the present invention the compound of the invention will normally be administered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or a pharmaceutically acceptable non-toxic acid addition salt, e.g. the hydrochloride, hydrobromide, lactate, acetate, phosphate, sulfate, sulfamate, citrate, tartrate, oxalate and the like in a pharmaceutically acceptable dosage form. The dosage form may be a solid, semisolid or liquid preparation. Usually the active sub25 stance will constitute between 0.1 and 99% by weight of the preparation, more specifically between 0.5 and 20% by weight for preparations intended for injection and between 0.2 and 50% by weight for preparations suitable for oral administration.
To produce pharmaceutical preparations containing the compound of the invention in the form of dosage units for oral application, the selected compound may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatine or poly-vinylpyrrolidone, and a lubricant such
BAD ORIGINAL &
AP 0 0 0 3 3 8 as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet can be coated with a polymer known to the man skilled in the art, dissolved in a readily volatile organic solvent or mixture of organic solvents. Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compound.
For the preparation of soft gelatine capsules, che active substance may be admixed with e.g. a vegetable oil or poly-ethylene glycol. Hard gelatine capsules may contain granules of the active substance using either the above mentioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatine. Also liquids or semisolids of the drug can be filled into hard gelatine capsules.
Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substance in a mixture with a neutral fatty base, or gelatine rectal capsules comprising the active substance in admixture with vegetable oil or paraffin oil. Liquid preparations for oral application may be in the form of syrups or suspensions, for example solutions containing from about 0.2% to about 20% by weight of the active substance herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl-cellulose as a
BAD ORIGINAL A thickening agent or other excipients known to the man in the art .
Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble p'narmaceut ica 1 ly acceptable salt of the active substance, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.
Suitable daily doses of the compound of the invention in therapeutical treatment of humans are about 0.01-100 mg/kg bodyweight at peroral administration and 0.001-100 mg'kg bodyweight at parenteral administration.
The invention is illustrated by the following working examples .
Example 1
3-(N-Isopropyl-N-n-propylamino)-5- (N-lsopropyl)carbamoyl chroman
a) 3-Isopropylamino-5-methoxychroman hydrochloride
5-Methoxy-3-chromanone (16 g, 0,089 mol) and isopropylamine (6,4 g, 0,112 mol) were reacted via reductive amination by known mehods (Clinton F. Lane Synthesis 1975 vol. 46 p. 135) to give the title compound. Mp. 255°C.
b) 3-(N-Isopropyl-N-n-propylamino)-5-methoxychroman
A mixture of the product obtained in a) above (14 g,
0,06 mol), 1-iodopropane (15 g, 0,08 mol), I^CO^ and acetonitrile (250 ml) was stirred under reflux for 4 days. After chromatography the desired product was isolated as a colourless oil. GC-MS(Ci-mode) M+l = 264 (100%) .
BAD ORIGINAL $
AP 0 0 Ο 3 3 8 c ) 3- (N-Isopropyl-N-n-propylamino) -5-hydroxychroman
The product from b) above (10 g, 0,038 mol) was demethylated using BBr^ in dichloromethane.
GC-MS(CI-mode) M+l - 25C (100%!.
d) 3- (N-Isopropyl-N-n-propylamino) -5-trifluoromethanesuIfonoxychroman
The product from c) above (10 g, 0,04 mol) was dissolved in CI^Clj and cooled to -30°C. pyridine (6 g, 0,076 mol) was added followed by trifluoromethanesulfonic anhydride (14 g, 0,05 mol). The solution was stirred at -20°C for 3 hours and then allowed to reach ambient temperature.
The solution was washed with aqueous NaHCO^, dried with Na-.SC, and evaporated to dryness. The oil was finally
J *1 J purified by fiash chromatography (silica gel) by elutioh with ethyl acetate/hexane 1:9.
GC-MS(CI-mode) M+l = 382 (100%)
e) 3- (N-Isopropyl-N-n-propylamino) - 5- (N-isopropyl)carbamoyl chroman
A mixture of the product from d) above (3 g; 0.008 mL) ,
1,3-bis (diphenylphosphine) propane (150 mg), palladium (II) acetate (75 mg), and isopropylamine (5 ml) ir. 30 ml DMF was placed in a Parr glass vessel. CO at 2 bar was added and the mixture was shaken at 60°C for 4 hours. After work up and chromatographic purification the desired compound was obtained as white crystals with mp 124 °C (base) .
Example 2 (R) -3- (N-Isopropyl-N-n-propylamino) -5- (N-isopropyl)carbamoylehroman (I) (Method A)
a) 3-Amino-5-methoxychroman hydrochloride (II)
3-Amino-5-methoxychroman was prepared according to known bad original s !
methods (Acta Pham. Suec. 24, 169-182, 1987; .
Mp: 237-238°C.
b) (R)-3-Amino-5-methoxychroman (III)
The racemic 3-amino-5-methoxychroman as base (1.0 g;
5.5 mmol) and L( + )tartanc acid (1.0 g; 6.6 mmol) were dissolved in water (20 ml). The solution was heated to 70°C and the clear solution was allowed to crystallize at room temperature overnight. The precipitate was filtered off giving 0.7 g of the tartrate salt with 99% optical purity of the (R)-isomer. Alkalization and extraction with CH2C12 drying (Na2SO4) and evaporation gave 0.35 g (35%) of the title compound as the free base.
[(1)^ = -20.8° (C=0.S3, CH2C12,.
c) (R) -3-(N-Isopropylamino)-5-methoxychroman (V) (R) -3-Amino-5-methoxychroman (1.0 g; 6mmol) and acetone (2.5 g; 40 mmol) were mixed with methanol (820 ml), acetic acid (0.4 g; 6.6 mmol) and NaCNBH^ (1.2 g;
mmol), pH was adjusted to 6.0 with acetic acid. Stirring was continued at room temperature for 3 days.
The mixture was evaporated and the residue was made alkaline and extracted with CH2C12. After drying (Na2SC4) and evaporation the title compound as base was transformed to the HCl-salt. Yield: 1.1 g (83%). Mp: 289° dec. [a)^5=-29° (C=0.015; MeOH)
d) (R) -3- (N-Isopropyl-N-n-propylamino) -5-methoxychroman (R)-3-(N-Isopropylamino)-5-methoxychroman (17.5 g, 0.079 mol) was dissolved in dimethylformamide (DMF) (180 mL) . K_CO7 (21.8 g, 0.18 mol) and 1-iodopropane (53.8 g,
0.32 mol) were added. The reaction mixture was then stirred at 50°C for 5 days. The solvent was removed in vacuo. The residue was dissolved in ether/NH^ (1 M). The
BAD ORIGINAL
ΑΡ 0 0 0 3 3 8 phases were separated and the water phase was washed once with ether. The combined ether-layers were dried (MgSO^! and the solvent was removed in vacuo to give a yellow oily residue. The oil was dissolved m dry ether and title compound was obtained in form of the HCl-salt in 66% yield (15.7 g) by slow addition of HCl in ether at G°C. Mp (HCl-salt): 108-120°C.
[a]25=(Base)=-95.5°(C = 0.l;MeOH).
e) (R)-5-Hydroxy-3-(N-isopropyl-N-n-propylamino) chroman
The HCl-salt of (R)-3-(N-isopropyl-N-n-propylamino)-5methoxychroman (15.5 g, 52 mmol) was mixed with CH2CI2 '100 mL} under nitrogen atmosphere and cooled to -66=5. BBr.j(27.2 g, 110 mmol) dissolved in C^C^ (50 mL) , was added slowly. The temperature was then raised to 0°C and the reaction mixture was stirred at 0°C for 12h. The reaction mixture was then slowly added to a stirred saturated NaHCO^ solution. The layers were separated and the water layer was extracted once with CHjClj. The combined organic layers were dried (MgSO4). Removal of the solvent in vacuo gave the phenolic title compound. Yield: 98%.
[a](Base)=-83.0° (C = 0.1;MeOH) .Mp(HCl-salt) : 215-222 = 5 (decomposes).
f) (R) -3- (N-isopropyl-N-n-propylamino) -5-trifluoromethane sulfonyloxychroman (VI) (R) -5-Hydroxy-3-(N-isopropyl-N-n-propylamino)chroman (13 g, 52 mmol) was dissolved in C^C^dOO mL) under nitrogen atmosphere. 2,4,6-Collidine (8.2 g, 68 mmol) was added and the mixture was cooled to -60°C. Trifluoromethanesulfonic anhydride (17.7 g, 62 mmol) was added slowly over a one hour period. The temperature was then raised to 0°C and the reaction was quenched with saturated ^2^3. The layers were separated. The water
BAD ORIGINAL ft ‘Ί t14 layer was pH adjusted with ΝΗ,(2 M) to pH 8 and extracted once with CH2C12· The combined organic layers were dried (MgSO^). Removal of solvent in vacuo gave a brown oily residue which was purified by flash chromatography SiQ.,'CH^Cl^) to give the triflate compound. Yield: 76% (15 g) .
[a]22=-77.9°{C=0.01;MeOH).
g) (R)-3-(H-Xeopropyl-N-n-propylamino)-5-(K-ieopropyl)carbamoylchroman (X) (R)-3-(N-Isopropyl-N-n-propylamino)5-trifluoromethanesulfonyloxychroman (5.2 g, 14 mmol) was dissolved in DMF (30 mb). Isopropylamine (10 mb) was added and the vessel was evacuated followed by inlet of CO-gas. This procedure was repeated twice before palladium (II) acetate (90 mg! and 1,3-bis(diphenylphosphino)propane (144 mg) was added. The reaction mixture was then stirred for lOh at 65°C.
The solvent was removed in vacuo. The dark brown residue was dissolved in diethylether/NH^ (1 M). The layers were separated and the water-phase was extracted once with ether. The combined ether layers were dried (MgSO^). Removal of solvent in vacuo gave a yellow crystalline residue which was purified by flash chromatography SiC(CH2CL2/EtOAc,10:1). Recrystallisation from CH2Cl2/hexane gave the pure amide (R)-3-(N-isopropylamino-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman. Yield: 35% (1.5 g).
[α]2χ = -87.0°(C = 0.1;MeOH) .Mp:94-95.4°C .
Exam.pl e 3 (R)-3-(N-Isopropylamino-N-n-propylamlno)-5-(N-isopropyl)carbamoylchroman (I) (Method B)
a) (R)-3-(N-Isopropylamino)-5-methoxychroman (V)
5-Methoxy-3-chromanone (50 g, 0,28 mol; described in
BAD ORIGINAL ft
AP 0 0 0 3 3 8
EP 0 222 996) was dissolved in methanol (300 mL). The solution was cooled to 0°C before the isopropylamine ί70 mL, excess) was added. The pH was adjusted to about 6 by the addition of acetic acid. NaCNBH^ (12 g, 0.19 mol) was added in portions during a one hour period and pH was kept at pH 6. The ice-bath was removed and the mixture was stirred overnight at room temperature. The solvent was removed in vacuo. The residue was dissolved in ether/NH^ (1 M) . The layers were separated and the amine in the ether layer was subjected to acid-base extraction (HCl(1M)/ΝΗ^(1M)). Drying with MgSO^ and evaporation of solvent gave an colorless crystalline product.
Yield: 87% (54 g). Mp: 255-56°C (HCl-salt of the racemic croduct) .
The racemic 3- (N-isopropylamino)-5-methoxychroman (IV;
g, 0.224 mol) was mixed with an equimolar amount of ( +) -di-1,4-toluoyl-D-tartaric acid (98.6 g, 0.244 mol). The mixture was dissolved in boiling ethanol (170 mL)/acetone (70 mL) . The salt started to crystallize in the hot solvent mixture but was not filtered off until the solvent had cooled down to room temperature (20°C) . The salt was then recrystallized nine times from ethanol/acetone (1:5) to give the pure diastereomeric salt. Yield: 35% (54 g) (99% e.e). Mp: 166-168°C. The free enantiomer as the base (R)-3-(N-isopropylamino)-5methoxychroman was obtained by the extraction of the salt in ether/KOH (1M). Yield: 32%, 17.5 g, [a] ^ = -32° (C = 0.1 ;MeOH) .
Mp. 285-286°C (HCl-salt)
b) (R) - 3- (N-Isopropyl-N-n-propylamino) - 5-methoxychroman
The title compound was prepared in the same way as described in Example lb and obtained in the same amount and with the same physical data as given in Example 2d.
BAD ORIGINAL &
Ί16
c) (R)- 5-Hydroxy-3 -(N-isopropyl-N-n-propylamino)chroman
The title compound was prepared in the same way as described in Example 2e and obtained in the same amount and with the same physical data as given m Example 2e.
d) (R)-3- (N-Isopropyl-N-n-propylamino)-5-trifluoromethanesulfonyloxychxoman (VI)
The title compound was prepared in the same way as described in Example 2f and obtained in the same amount and with the same physical data as given in Example 2f.
e) (R)-3- (3-N-Isopropyl-N-n-propylamino)-5-(N-iso15 propylJcarbaunoylchroman (I)
The title compound was prepared in the same way as described in Example 2g and obtained in the same amount and with the same physical data as given in Example 2g.
Example 4
a) (R) -3- (N-Isopropyl, N-n-propylamino) - 5-me thoxycarbonylchroman (R) -3- (N-Isopropyl,N-n-propylamino) -5-trifluoromethanesulfonyloxychroman (4.0 g, 10.5 mmol), triethylamine (2.3 g, 23.1 mmol) and a mixture of DMF/MeOH (18 mL, 6:2) was mixed in a three necked round-bottom flask. The flask was evacuated followed by inlet of CO-gas (repeated two times). Finally 1,3-bis(diphenylphosphino)propane (0.11 g) and palladium(II) acetate (0.07 g) was added. The mixture was stirred at 70°C for 17 hours. The reaction mixture was diluted with diethyl ether, washed with 2M
NHj and dried (MgSCty) . Removal of solvent in vacuo gave a brown oily residue which was purified by flash chromatography (SiC^, CH2Cl2/EtOAc; 10:1) to give the title
BA© Original ft
AP Ο Ο Ο 3 3 8 compound in 82% yield (2.5 g) .
[α( = -131.6° (MeCH, 0.1M).
GC-MS (70eV) =291 - . 262 (100%)
b) (R)-3-(N-Isopropyl,N-n-propylamino)-5-N-isopropyl) carbamoylchroman (I) (R)-3-N-(N-Isopropyl,N-n-propylamino)-5-methoxycarbonylchroman (0.46 g, 1.6 mmol), dissolved in MeOH (lOmL), was mixed with a solution of NaOH (0.06 g,
1.6 mmol) in water (3 mL). The reaction mixture was then refluxed for 3.5 hours before the solvent was removed in vacuo. The residue was dissolved in toluene. The toluene was removed in vacuo (repeated two times) in order to
1; term. ar. azeotrope to remove the water. The residue was then dissolved in SOCI2 (5 mL) and refluxed for 1 hour. The excess of SOCI2 was removed in vacuo. The residue was dissolved in CH2CI2 (20mL, dried with molecular sieves before 4 mL isepropylamine was added. The reaction
2G mixture was stirred for 1 hour at room temperature (21°C) before it was diluted with diethyl ether, washed (2M NH3) and dried (MgSO^). Removal of solvent in vacuo gave a yellow oily residue which was purified by flash chromate-
2·'Ξο3Αο; 5:2) to give the pure compound in 88% yield (0.46 g).
[0)^ = -90.4° (MeOH 0.1) .Mp:93-94°C.
Pharmacology
Pharmacological treatment of depression in man
Evidence is available that in depressed patients the neurotransmission in the central nervous system (CNS) may be disturbed. These disturbances appear to involve the neurotransmitters noradrenaline (NA) and 5-hydroxytryptamine (5-HT). The drugs most frequently used in the treatment of depression are considered to act by improving the neurotransmission of either or both of
BAD ORIGINAL these physiclogical agonists. Available data suggest that the enhancement of 5-HT neurotransmission will primarily improve the depressed mood and anxiety, whereas the enhancement cf noradrenaline neurot ransm.ission will rather improve the retardation symptoms occurring in depressed patients. In recent years many efforts have been made to develop new drugs with high selectivity for improvement of 5-HT neurotransmission in the CNS.
The dominating mechanism of action for the drugs generally used today in the therapy of mental depression is by blocking the reuptake of the endogenous neurotransmitters (NA and/or 5-HT) released from nerve terminals it. the CNS, thus increasing the concentration of these transmitters in the synaptic cleft and hence restoring an adequate neurotransmission.
A fundamentally different way to improve the neurotransmission in the central 5-HT-neurons would be to use a direct 5-HT-receptor agonist. In order to minimize side effects, a high selectivity for this kind of receptors would then be preferable.
Surprisingly, we have found that the racemate as well as the (R)-enantiomer of the compound 3-(N-isopropyl-N-npropylamino)-5- (N-isopropyl) carbamoylchroman has show high stereo selective, direct stimulating effect on the
5-KT.-receptors in CNS combined with a good bicavailIA ability.
In vitro test: Receptor binding assay
In order to evaluate the 5-HT-receptor stimulating effect and selectivity, the affinity for various receptors in rat brain were measured in vitro using receptor assay.
The stereospecific (R)-enantiomeric compound of the
BAD ORIGINAL $
AP Ο Ο Ο 3 3 8 invention (R)-3 -(Ν-isopropyl-N-n-p ropylamino)-5 -(M-isopropy1)carbamoylchroman has IC 8.6 (nM) and the racemic compound 3-(N-isopropyl-N-n-propy1 amino)-5-(N-isopropyl) carbamoylchroman has fC 24 (nM) . The valve for the (Sι-enantiomer exceeded 1000 nM.
Method: 5HT^a binding assay. Cerebral cortex + hippocampus from each rat was dissected and homogenized in 15 ml ice-cold 50 mM Tris-HCl buffer 4.0 mM CaC^ and
5.7 mM ascorbic acid, pH 7.5 with an Ultra-Turrax (Janke & Kunkel, Staufen, FRG) for ten s. After centrifugation for 12.5 min at 17,000 rpm (39,800 x g in a Beckman centrifuge with a chilled JA-17 rotor (Beckman, Palo Alto, CA, USA), the pellets were resuspended in tne same buffer and homogenization and centrifugation repeated. To each pellet 5 ml ice-cold 0.32 M sucrose were added and homogenized for 5 sec. These samples were kept frozen at -70°C. When used they were diluted with the buffer to 8 mg tissue/ml and homogenized for 10 sec.
The tissue homogenates were incubated for ten minutes at 37°C and then supplied with 10 μΜ pargyline followed by reincubation for 10 minutes.
The binding assay followed that described by Peroutka,
J. Neurochem. 47, 529-540, (1986). The incubation mixture (2 ml) contained ^H-8-OH-DPAT (0.25 to 8 nM), 5 mg/ml tissue homogenate in 50 mM Tris-HCl buffer containing
4.0 mM CaCl9 and 5.7 mM ascorbic acid, pH 7.5. Six Z 3 different concentrations of H-8-OH-DPAT were analyzed.
Binding experiments were started by the addition of tissue homogenate and followed by incubation at 37°C for 10 minutes. The incubation mixtures were filtered through Whatman GF/B glass filters with Brandel Cell Harvester (Gaithersburg, MD, USA). The filters were washed twice with 5 ml ice-cold 50mM Tris-HCl buffer, pH 7.5, and counted with 5 ml Ready-solv HP (Beckman) in a Beckman
LS 3801 scintillation counter. Non-specific binding was
BAD ORIGINAL ft •measured by the addition of 10 μΜ 5-HT to the reaction mixture. The binding data was processed by non-linear least squares computer analysis (Munson and Rodbard,
Anal. Eiochem. 107, 220-239, (1980).
In vivo test: Oral bioavailability in dogs
The bioavailability test was performed as described below and gives the mean value of 17% for the (R)-enantiomer and 21% for the racemate of compound 3-(N-isopropyl-N-npropylamino)-5-(N-isopropyl)carbamoylchroman based on plasma level measurements in dogs. Dose-effect studies in rat following subcutaneous versus oral administration further support a high availability of the compound at the receptor after oral administration.
Method: Assessment for oral bioavailability (systemic availability) was based on the plasma area under the curve (AUC) method. An aqueous saline solution of compound of the invention was administered intravenously (i.v.) and orally (p.o.) to the animals and concentrations of the compound in plasma measured at numerous timepoints. The doses administered were 1 pmol’kg”^ ano 10 pmol'kg for intravenous and oral administration, respectively. AUC was calculated according to the trapezoidal rule. Determination of the test compound in plasma was accomplished by an HPLC method which incorporated electrochemical detection.
In vivo test: Synthesis of 5-HT
As predicted for a selective 5-HTia agonist, the synthesis rate of 5-HT, measured as a significant decrease of the 5-HTP level in rat brain was recorded after 0,1 mg/kg following subcutaneous administrations as well as after 0,2 mg/kg oral administration of the (R)-enantiomer of compound 3-(N-isopropyl-N-n-propylbad original $
AP 0 0 0 3 3 8 amino) -5-(N-isopropyl) carbamcylchroman
Method: The rate of synthesis of 5-H7 in the rat streafum was measured as the accumulation of 5-HTP during 30 min after inhibition of aromatic L-ammo acid decarboxylase by NSD 1015 (decarboxylase inhibitor, 100 .mg/kg i.e·.·.
The test compound was administered 30 min before the NSD 1015. The regions of the brain to be examined were dissected, frozen and stored.
The levels of 5-HTP {5-hydroxytryptophan) was determined by use of high performance liquid chromatography (HPLC. with electrochemical detection according to the method cf Magnusson, Nilsson and Westeriund (1380) . The motile phase was 0,1 M phosphate buffer (pH 2,5):methanoi:ace-cnitrile-89:9:2 v/v, containing ImM octylsulphate. The frozen samples were weighed and homogenized in 0,1 M perchloric acid, containing 2,5 nM sodium bisulphite, mM ethylene diamine tetraacetic acid (EDTA) and epimr.e as an internal standard. The supernatants were injected directly onto a Supelcosil C^g (3 μΜ) column, connected to a detector (ESA Coulochem 5100A), set to 0,05/0,40 V.
Temperature effects
A significant temperature decrease was obtained in rats following subcutaneous administration of 0.3 mg/kg or 1 mg/kg using oral administration of the (R)-enantiomer of compound 3- (N-isopropyl-N-n-propylamino) -5-(N-isopropyl )carbamoylchroman.
Method: In each test, thirty rats, weighing approx 250 g, housed in 6 cages of 5 rats, are used. The rats have free access to food and water. Before the start of testing, they are numbered and left undisturbed for at last 1 hour. Before the administration of the compound, the body temperature of each rat is measured using a YSI 2100
BAD ORIGINAL ft tele-thermometer. The thermometer probe is inserted 11 into the rectum and left in pace for thirty seconds. The drug is then administered either subcutaneously or orally. In each experiment vehicle and 4 doses of drug are tested. One rat in each cage receives each treatment. The order of treatment is rotated since disturbance to the cage increases the activity of the rats, and thereby their body temperature. Thirty minutes after drug administration the rats' body temperature are measured again. The procedure is repeated 60, 90 and 120 minutes after drug administration. The resultant data on body temperature is subjected to analysis of variance. A significant group by time interaction is taken as an mdioasion of drug effect. To obtain the minimum effective dose, the mean temperature for each cf the drug treated groups are compared with that of the vehicle group at each time point using Dunnett's t-test with a level of significance of p<0.02. An indication of bioavailability may be obtained by calculating the ratio between the minimum effective doses following oral and subcutaneous administration.
Claims (11)
1. 3-(N-isopropyl-N-n-propylamino)-5-(Nisopropyl)carbamoylchroman having the formula I as a racemate, or (R)-enantiomer in the form of a free base or a pharmaceutically acceptable salt thereof.
2. 3-(N-isopropyl-N-n-propylamino)-5-(Nisopropyl)carbamoylchroman in the form of a free base or a pharmaceutically acceptable salt.
3 . (R) -3-(N-isopropyl-N-n-propylamino) -5-(Nisopropyl)-carbamoylchroman in the form of the free base or a pharmaceutically acceptable salt.
4. A pharmaceutical composition containing, as active ingredient, a compound as claimed in any of claims 1 to 3 .
disorders.
8. A compound as claimed in claim 7 for use in the treatment of depression, anxiety, anorexia, senile dementia, migraine, obsessive-compulsive disorder, stroke, Alzheimer's disease, hypertension, thermoregulatory or sexual disturbances, pain or disturbances in the cardiovascular system.
BAD ORIGINAL Q
9. Use of a compound as defined in any of claims 1 to 3 in the manufacture of a medicament for treatment of disorders in the central nervous system, especially 5-hydroxytryptamine mediated disorders. '
5 10. Use accordihg to claim 9 for the manufacture of a medicament for treatment of depression, anxiety, anorexia, senile dementia, migraine, obsessive-compulsive disorder, stroke, Alzheimer's disease, thermoregulatory or sexual disturbances, pain or disturbances in the
10 cardiovascular system.
11. A process for the preparation of a compound as claimed in any of claims 1 to 3 which process comprises:
i. converting a compound of formula VI (VI) wherein Y is a leaving group, by catalytic cycle using a 15 zerovalent transition metal, treatment with carbon monoxide, followed by amination, or ii .
amination of a compound of formula VII wherein Z is Cl, Br, OH or isopropylamine to give the
ORp, where Rp is C,-C6 alkyl, compound of formula I, with
BAD ORIGINAL ffi (Vii) / 1»..,-, .... _____
APO00338
- 25 and, if necessary or desired, converting the product obtained into a salt.
12. A process according to claim 11 wherein 3(N,N-isopropyl,n-propylamino)-55 trifluoromethanesulfonoxychroman is aminated with isopropylamine to give a compound as claimed in claim 1.
13. A compound according to any of claims 1 to 3 prepared by the process claimed in claim 11 or 12.
14. A process for preparing (R)-3-amino-510 methoxychroman which process comprises dissolving racemic 3amino-5-methoxychroman and L(+)tartaric acid in water,, heating to obtain a clear solution and allowing the clear solution to crystallise at room temperature.
15. (R)-3-Amino-5-methoxychroman prepared by the
15 process claimed in claim 14.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9102905A SE9102905D0 (en) | 1991-10-08 | 1991-10-08 | A NEW THERAPEUTICALLY ACTIVE COMPOUND AND A PROCESS FOR ITS PREPARATION |
| SE9202000A SE9202000D0 (en) | 1992-06-29 | 1992-06-29 | A NEW THERAPEUTICALLY ACTIVE COMPOUND |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9200434A0 AP9200434A0 (en) | 1992-10-31 |
| AP338A true AP338A (en) | 1994-04-26 |
Family
ID=26661197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1992/000434A AP338A (en) | 1991-10-08 | 1992-10-08 | A carbamoylchroman compound as selective 5-hydroxytryptamine. |
Country Status (32)
| Country | Link |
|---|---|
| EP (3) | EP0538222A1 (en) |
| JP (1) | JPH07500320A (en) |
| CN (2) | CN1072411A (en) |
| AP (1) | AP338A (en) |
| AT (1) | ATE139774T1 (en) |
| AU (1) | AU667687B2 (en) |
| BG (1) | BG98684A (en) |
| CA (1) | CA2118708A1 (en) |
| CY (1) | CY1992A (en) |
| CZ (1) | CZ51094A3 (en) |
| DE (1) | DE69211857T2 (en) |
| DK (1) | DK0607274T3 (en) |
| EE (1) | EE02981B1 (en) |
| ES (1) | ES2089571T3 (en) |
| FI (1) | FI941616A7 (en) |
| GR (1) | GR3020608T3 (en) |
| HK (1) | HK55997A (en) |
| HR (1) | HRP920935A2 (en) |
| HU (1) | HUT68834A (en) |
| IL (1) | IL103373A0 (en) |
| IS (2) | IS1644B (en) |
| MA (1) | MA22674A1 (en) |
| MX (1) | MX9205744A (en) |
| MY (1) | MY131174A (en) |
| NO (1) | NO941256D0 (en) |
| NZ (2) | NZ270595A (en) |
| PL (1) | PL171013B1 (en) |
| SI (1) | SI9200249A (en) |
| SK (1) | SK36194A3 (en) |
| TN (1) | TNSN92088A1 (en) |
| WO (1) | WO1993007135A1 (en) |
| YU (1) | YU90492A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420151A (en) * | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
| US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| CA2345079C (en) * | 1998-09-23 | 2011-06-21 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6235938B1 (en) * | 1999-06-10 | 2001-05-22 | Yale University | Transition metal-catalyzed process for preparing N-aryl amine compounds |
| SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| EA202090414A1 (en) | 2017-08-02 | 2020-05-28 | Суновион Фармасьютикалз Инк. | COMPOUNDS AND THEIR APPLICATION |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009853A1 (en) * | 1989-12-22 | 1991-07-11 | Aktiebolaget Astra | New chroman and thiochroman derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3679378D1 (en) * | 1985-09-03 | 1991-06-27 | Ciba Geigy Ag | 3-AMINO-DIHYDRO- (1) -BENZOPYRANE AND BENZOTHIOPYRANE. |
| US4801605A (en) * | 1986-08-29 | 1989-01-31 | Ciba-Geigy Corporation | 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans |
| SE8605504D0 (en) * | 1986-12-19 | 1986-12-19 | Astra Laekemedel Ab | NOVEL CHROMAN DERIVATIVES |
| JPH021429A (en) * | 1988-06-09 | 1990-01-05 | Toray Ind Inc | Production of optically active 1-methyl-3-phenylpropylamine |
-
1992
- 1992-10-02 HR HR920935A patent/HRP920935A2/en not_active Application Discontinuation
- 1992-10-05 NZ NZ270595A patent/NZ270595A/en unknown
- 1992-10-05 NZ NZ244618A patent/NZ244618A/en unknown
- 1992-10-05 MY MYPI92001795A patent/MY131174A/en unknown
- 1992-10-07 IS IS3929A patent/IS1644B/en unknown
- 1992-10-07 MA MA22959A patent/MA22674A1/en unknown
- 1992-10-07 MX MX9205744A patent/MX9205744A/en unknown
- 1992-10-08 EP EP92850237A patent/EP0538222A1/en active Pending
- 1992-10-08 ES ES92921525T patent/ES2089571T3/en not_active Expired - Lifetime
- 1992-10-08 JP JP5506849A patent/JPH07500320A/en active Pending
- 1992-10-08 CZ CZ94510A patent/CZ51094A3/en unknown
- 1992-10-08 WO PCT/SE1992/000708 patent/WO1993007135A1/en not_active Application Discontinuation
- 1992-10-08 HU HU9400993A patent/HUT68834A/en unknown
- 1992-10-08 CN CN92112826A patent/CN1072411A/en active Pending
- 1992-10-08 CA CA002118708A patent/CA2118708A1/en not_active Abandoned
- 1992-10-08 DE DE69211857T patent/DE69211857T2/en not_active Expired - Fee Related
- 1992-10-08 SK SK361-94A patent/SK36194A3/en unknown
- 1992-10-08 AP APAP/P/1992/000434A patent/AP338A/en active
- 1992-10-08 TN TNTNSN92088A patent/TNSN92088A1/en unknown
- 1992-10-08 EP EP92921525A patent/EP0607274B1/en not_active Expired - Lifetime
- 1992-10-08 DK DK92921525.9T patent/DK0607274T3/en active
- 1992-10-08 IL IL103373A patent/IL103373A0/en unknown
- 1992-10-08 AT AT92921525T patent/ATE139774T1/en not_active IP Right Cessation
- 1992-10-08 SI SI19929200249A patent/SI9200249A/en unknown
- 1992-10-08 PL PL92303101A patent/PL171013B1/en unknown
- 1992-10-08 AU AU27684/92A patent/AU667687B2/en not_active Ceased
- 1992-10-08 YU YU90492A patent/YU90492A/en unknown
- 1992-10-08 EP EP95118114A patent/EP0703229A3/en not_active Withdrawn
- 1992-12-08 IS IS4310A patent/IS4310A/en unknown
-
1994
- 1994-03-29 BG BG98684A patent/BG98684A/en unknown
- 1994-04-07 NO NO941256A patent/NO941256D0/en unknown
- 1994-04-08 FI FI941616A patent/FI941616A7/en not_active Application Discontinuation
- 1994-11-23 EE EE9400368A patent/EE02981B1/en unknown
-
1996
- 1996-02-28 CN CN96103466A patent/CN1146992A/en active Pending
- 1996-07-23 GR GR960401967T patent/GR3020608T3/en unknown
-
1997
- 1997-05-01 HK HK55997A patent/HK55997A/en not_active IP Right Cessation
- 1997-09-05 CY CY199297A patent/CY1992A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009853A1 (en) * | 1989-12-22 | 1991-07-11 | Aktiebolaget Astra | New chroman and thiochroman derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5650524A (en) | Process for preparing (R)-3-amino-5-methoxychroman | |
| SK10302001A3 (en) | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | |
| US5962514A (en) | Combination of 5-HT uptake inhibitor with a selective 5-HT1A antagonist | |
| FR2832713A1 (en) | New 4-(1,3,4-thiadiazol-2-yl)-1,4-diaza-bicyclo(3.2.2)nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia | |
| SI9012429A (en) | New chroman and thiochroman derivatives | |
| FR2832712A1 (en) | New 4-(1,2,4-oxadiazol-3-yl)-1,4-diaza-bicyclo (3.2.2) nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia | |
| CZ286038B6 (en) | Derivative of 2-aminotetralin being substituted in position 8, process of its preparation, pharmaceutical preparation containing thereof as well as its use | |
| AP338A (en) | A carbamoylchroman compound as selective 5-hydroxytryptamine. | |
| WO2006010968A1 (en) | New aryloxy acetic acid amide derivatives | |
| US5616610A (en) | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans | |
| JP7714727B2 (en) | Solid Forms of GlyT1 Inhibitors | |
| JP3786984B2 (en) | Piperazine derivatives | |
| HK1002898B (en) | Novel (r)-5-carbamoyl-8-fluoro-3-n, n-disubstituted-amino-3,4-dihydro-2h-1benzopyranes |